XDR-TB Extensively Drug-Resistant Tuberculosis

What, Where, How and Action Steps…

Countries with XDR-TB Confirmed cases to date

Czech Republic

The b

oundarie

s and n

am

es sh

ow

n a

nd th

e d

esig

natio

ns u

sed o

n th

is map d

o n

ot im

ply

the e

xpre

ssion o

f any o

pin

ion

whatso

ever o

n th

e p

art o

f the W

HO

conce

rnin

g th

e le

gal sta

tus o

f any co

untry

, territo

ry, city

or a

rea o

r of its a

uth

oritie

s, or co

nce

rnin

g th

e d

elim

itatio

n o

f its frontie

rs or b

oundarie

s. Dotte

d lin

es o

n m

aps re

pre

sent a

ppro

xim

ate

bord

er lin

es fo

r w

hich

there

may n

ot y

et b

e fu

ll agre

em

ent.

WH

O 2

005. A

ll rights re

serv

ed

Ecuador

Georgia

Argentina

Bangladesh

Germany

Republic of Korea

Armenia

Russian Federation

South Africa

Portugal

Latvia

Mexico

Peru USA

Brazil

UK

Sweden

Thailand

Chile

Based on information provided to WHO Stop TB Department March 2007

Spain

Islamic Republic of Iran

China, Hong Kong SAR

France

Japan

Norway

Canada

Italy

Emergence of XDR-TB March 2006

Of 17,690 isolates from 49 countries during 2000-2004, 20% were MDR-TB and 2% were XDR-TB

XDR-TB found in: USA: 4% of MDR-TBLatvia: 19% of MDR-TBS Korea: 15% of MDR-TB

MDR-TB = resistance to at least isoniazid and rifampicin, the two most powerful first-line anti-TB drugs

XDR = Multidrug-resistant TB (MDR-TB) plus resistance to (i) any fluoroquinolone, and (ii) at least 1 of 3 injectable second-line drugs capreomycin, kanamycin, amikacin (new definition agreed October 2006)

XDR-TB in Southern AfricaAugust 2006

• 53 of 544 patients defined as XDR-TB cases• 52 of the 53 patients died on average within 25 days, including those on antiretroviral therapy• Further investigations being carried out• XDR-TB likely in bordering African countries

Church of Scotland Hospital, Tugela Ferry,KwaZulu-Natal Province, South Africa

Given the underlying HIV epidemic in Africa, drug-resistant TB could have a major impact on mortality and

requires urgent action on care and prevention

WHO Stop TB Strategy addresses drug resistance by strengthening TB control

The Stop TB Strategy strengthens TB control,preventing the emergence of drug-resistant TB…

…and underpins the Stop TB Partnership's Global Plan to Stop TB 2006-2015,

to treat 50 million patients and save 14 million lives

The Stop TB Strategy & The Global Plan

International response to the XDR-TB emergency

WHO Global Task Force on XDR-TB, October 2006

• Ensure adherence to WHO drug resistance guidelines, improve programme management, access to MDR-TB drugs under proper conditions including direct observation. Ensure all patients with HIV are adequately treated for TB and started on antiretroviral therapy

• Accelerate implementation of infection control measures to reduce transmission especially among those HIV positive

• Accelerate access to rapid tests for rifampicin resistance

• Strengthen laboratory capacity to diagnose, manage and survey drug resistance. Commence rapid survey so that the size of the XDR-TB epidemic can be determined

• Initiate information-sharing strategies that promote prevention, treatment and control of XDR-TB

"Priority for the immediate strengthening of TB control in countries"

Resources needed in 2007 to respond to the XDR-TB emergency

Estimated needs for 14 Southern African Development Community countries from November 2006 to end 2007 US$

Costs in the 14 countries:

•$35m: Strengthening XDR-TB response: human resources development, lab strengthening, infection control, surveillance, monitoring and evaluation, community health, cross border collaboration, communication and health education etc. •$40m: Second line anti-TB drugs to 9,000 MDR-TB and XDR-TB patients •$ 5m: Rapid diagnostic tests to 154,000 MDR-TB and XDR-TB suspects

$80 million

Technical assistance costs (coordinated by WHO and provided by WHO and partners):

$9,460,000: Strengthening of general TB and TB/HIV control in countries most affected by XDR-TB by provision of technical assistance by international organizations and human resource development •$ 450,000: Revision of the Global Plan to Stop TB to reflect XDR-TB (not restricted to Africa) •$1,230,000: Support for management of persons suspected of having MDR-TB or XDR-TB •$1,200,000: Laboratory strengthening: development/revision of global and country strategic plans, strengthening of the global Supranational TB Reference Laboratory Network•$ 375,000: Infection control: updating of guidelines, training of consultants•$1,700,000: XDR-TB surveillance: establishment of regional reference laboratories in the African Region, support to countries by the Supranational Reference Laboratory Network, rapid XDR-TB surveys•$ 285,000: Advocacy, communication and social mobilization: communication support, advocacy materials, health education tools etc.•$ 100,000: Planning and resource mobilization support and coordination of partners•$ 200,000: Research and Development Strategy: meeting with TB diagnostics, drugs and vaccine working groups and partners

$15 million

TOTAL $95 million

XDR-TBThe Facts

• Drug-resistant TB poses a grave public health threat especially in populations with high HIV rates

• XDR-TB occurs as a result of poorly-managed TB control programmes

• XDR-TB, if identified early, can be treated and cured in some cases under proper TB control conditions, based on the experiences in a few successful programmes where HIV prevalence was low

• Infection control measures must be strengthened everywhere, and especially where HIV prevalence is high, to protect the vulnerable and those at risk of XDR-TB

• XDR-TB strains have been found in all regions of the world, although still thought to be uncommon

• XDR-TB underlines the need for investment in the development of new TB diagnostics, treatments and vaccines, since the current tools are outdated and insufficient

World Health OrganizationLeading the fight against TB and XDR-TB

"WHO is absolutely committed to supporting country efforts to fight TB in all forms"

Dr Anders NordströmWHO Acting Director-General Address to the Global Task Force on XDR-TB

"We will build greater momentum to control malaria, TB and neglected diseases"

Dr Margaret ChanWHO Director-General Elect Acceptance speech to the World Health Assembly

"WHO Stop TB, with full resources in place, will ensure the response to the XDR-TB emergency is effective and robust"

Dr Mario RaviglioneWHO DirectorStop TB Department

XDR-TBFor more information:

WHO Stop TB:for latest XDR-TB data, country reports,

monthly updates, guidelines, FAQs,

www.who.int/tb

Email: thomasg@who.int

Stop TB Partnership:for information on XDR-TB activities of the Partnership's

Working Groups and

its 500 partners

www.stoptb.org

Email: stoptbinfo@who.int